CureVac NV's revenue for the
three
months ended in Dec. 2023 was $24.61 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $58.05 Mil.
CureVac NV's Revenue per Share for the
three
months ended in Dec. 2023 was $0.11.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26.
Warning Sign:
CureVac NV revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of CureVac NV was -29.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -16.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 32.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, CureVac NV's highest 3-Year average Revenue per Share Growth Rate was 96.10% per year. The lowest was -16.20% per year. And the median was 50.90% per year.
CureVac NV Revenue Historical Data
The historical data trend for CureVac NV's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CureVac NV's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CureVac NV's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CureVac NV's Revenue distribution charts can be found below:
* The bar in red indicates where CureVac NV's Revenue falls into.
CureVac NV Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CureVac NV (NAS:CVAC) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
CureVac NV Revenue Related Terms
Thank you for viewing the detailed overview of CureVac NV's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CVAC has been successfully added to your 